Nuclear Medicine Therapy

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. A Study to Evaluate 177Lu-PSMA-R2 in Patients with PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer

   Rochester, Minn.

   The purpose of this study is to determine the safety, tolerability and pharmacokinetics (how the study drug and imaging agent is absorbed, moves, and is eliminated by your body can be analyzed) and dosimetry (how much radiation taken by the organs and tumors can be measured) of the study drug 177Lu-PSMA-R2 and imaging agent 68Ga-PSMA-R2 in subjects who have progressive metastatic castration-resistant prostate cancer

2. A Study to Develop and Validate Hybrid Molecular Imaging to Transform the Care of Hepatocellular Carcinoma Patients

   Rochester, Minn.

   The primary purpose of this study is to evaluate diagnostic performance of 68Ga-PSMA-dual contrast (gadavist and gadoxetate) PET/MRI OR PET/CT for HCC using surgical histopathology (either resection, transplant or biopsy specimens) or LI-RADS® categorization as gold standard.

3. A Study of 68GA-PSMA-Gadoxetate PET/MR or PET/CT for Evaluation of Hepatocellular Carcinoma

   Rochester, Minn.

   The primary purpose of this trial is to demonstrate the feasibility of integrated 68Ga-PSMA-gadoxetate PET/MRI ot PET/CT for imaging patients with Hepatocellular Carcinoma (HCC), and to compare the accuracy of 68Ga-PSMA-gadoxetate PET/MRI with MRI for staging of HCC.

4. Ga-DOTATATE PET for Localization of Phosphaturic Mesenchymal Tumors in Patients with Tumor Induced Osteomalacia

   Rochester, Minn.

   This study aims to identify cases of FGF23-mediated oncogenic osteoomalacia in which the underlying phosphaturic mesenchymal has not been found and perform 68Ga-DOTATATE PET in these patients to localize the tumor.

5. A Study to Evaluate CHIP and Hematological Toxicity After PRRT in Neuroendocrine Tumor Patients

   Rochester, Minn., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to combine robust clinical data (e.g., prior chemotherapy or radiation exposure, cumulative Peptide Receptor Radionuclide Therapy (PRRT dose)) with genetic and clonal abnormalities (blood-based CHIP panel) in studying the predisposing risk factors for developing hematological toxicity including t-MN in PRRT-treated neuroendocrine tumor (NET) patients.

6. A Study of Lutetium Lu 177 Dotatate (Lutathera®) in Patients with Inoperable, Progressive Meningioma after External Beam Radiation Therapy

   Rochester, Minn.

   The purpose of this study is to estimate the efficacy of LUTATHERA treatment in patients with recurrent grade 1 meningioma as measured by 6-month PFS rate, and to estimate the efficacy of LUTATHERA treatment in patients with recurrent grade 2 or 3 meningioma as measured by 6-month PFS rate.

    

7. Study to Evaluate the Efficacy and Safety of Lutathera in Patients with Grade 2 and Grade 3 Advanced GEP-NET

   Rochester, Minn.

   The purpose of this study is to determine if Lutathera in combination with long-acting octreotide prolongs PFS in GEP-NET patients with high proliferation rate tumors (G2 and G3), when given as a first line treatment compared to treatment with high dose (60 mg) long-acting octreotide. Somatostatin analog (SSA) naive patients are eligible, as well as patients previously treated with SSAs in the absence of progression.